Autoimmune Hepatitis Clinical Trial
Official title:
Development and Validation of a Machine Learning Model to Differentiate Drug-induced Liver Injury and Autoimmune Hepatitis
| NCT number | NCT05532345 |
| Other study ID # | 2022-P2-263-01 |
| Secondary ID | |
| Status | Completed |
| Phase | |
| First received | |
| Last updated | |
| Start date | July 1, 2022 |
| Est. completion date | May 31, 2023 |
| Verified date | July 2023 |
| Source | Beijing Friendship Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
A retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis. A machine learning-based tool will be developed and validated to help clinicians to differentiate between Drug-induced liver injury and Autoimmune hepatitis
| Status | Completed |
| Enrollment | 2583 |
| Est. completion date | May 31, 2023 |
| Est. primary completion date | May 31, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Drug-induced liver injury 1. RUCAM =6 and met one of the following biochemical conditions: a.) ALT=5 ULN, b.) or ALP =2 ULN, iii) or ALT=3 ULN and TBil=2 ULN. 2. RUCAM was between 3-5, the medical records were further reviewed by the three authors to determine the eligibility. - Autoimmune hepatitis 1. The revised International Autoimmune Hepatitis Group (IAIHG) diagnostic score=6 points. 2. Liver biopsy available, which is compatible with typical features of AIH. 3. If liver biopsy was unavailable, patients who achieved biochemical resolution after sustained immunosuppressive therapy. Exclusion Criteria: - Drug-induced liver injury 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male >40g/d, female >20g/d, and =5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Autoimmune hepatitis. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases. - Autoimmune hepatitis 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male >40g/d, female >20g/d, and =5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Drug-induced liver injury. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases. |
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Friendship Hospital, Capital Medical University | Beijing |
| Lead Sponsor | Collaborator |
|---|---|
| Beijing Friendship Hospital |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Accuracy of the model in the differential diagnosis of DILI and AIH | The ratio of the correct number of forecasts to the total number of forecasts | May 31, 2023 | |
| Primary | The confidence of the model in the differential diagnosis of DILI and AIH | The confidence and 95% confidence internal of the model in determining whether each case is DILI or AIH | May 31, 2023 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06020976 -
Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
|
||
| Recruiting |
NCT05476900 -
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
|
Phase 2 | |
| Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
| Recruiting |
NCT06250309 -
Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients
|
N/A | |
| Recruiting |
NCT01661842 -
Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis
|
Phase 1/Phase 2 | |
| Terminated |
NCT04339621 -
AIH Risk Stratification With Multiparametric MRI
|
||
| Not yet recruiting |
NCT04371718 -
Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)
|
Phase 2 | |
| Completed |
NCT02239562 -
sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS
|
Phase 1 | |
| Recruiting |
NCT05569759 -
A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
|
Phase 2 | |
| Completed |
NCT02463331 -
Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis
|
Phase 4 | |
| Not yet recruiting |
NCT06356506 -
A Study on Factors of Biochemical Response in Autoimmune Hepatitis
|
||
| Terminated |
NCT04203875 -
Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis
|
Phase 1 | |
| Recruiting |
NCT06078098 -
Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
|
||
| Completed |
NCT00838214 -
Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05810480 -
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
|
||
| Recruiting |
NCT03743272 -
Repeatability and Reproducibility of Multiparametric MRI
|
||
| Completed |
NCT03979053 -
Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
|
||
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Recruiting |
NCT04933292 -
A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT06455280 -
SIPLIZUMAB in AILD and LT
|
Phase 1 |